These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25581730)

  • 21. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
    Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
    Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
    Kluk MJ; Ho C; Yu H; Chen BJ; Neuberg DS; Dal Cin P; Woda BA; Pinkus GS; Rodig SJ
    Am J Clin Pathol; 2016 Feb; 145(2):166-79. PubMed ID: 26834124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.
    Agostinelli C; Rizvi H; Paterson J; Shende V; Akarca AU; Agostini E; Fuligni F; Righi S; Spagnolo S; Piccaluga PP; Clark EA; Pileri SA; Marafioti T
    Am J Surg Pathol; 2014 Oct; 38(10):1349-59. PubMed ID: 25118816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population.
    Naeini YB; Wu A; O'Malley DP
    Ann Diagn Pathol; 2016 Dec; 25():7-14. PubMed ID: 27806850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.
    Choi SY; Kim SJ; Kim WS; Kim K; Ko YH
    Virchows Arch; 2011 Nov; 459(5):495-502. PubMed ID: 22002677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Patients with MYC-Altered Lymphomas.
    Landsburg DJ
    Curr Hematol Malig Rep; 2016 Jun; 11(3):208-17. PubMed ID: 26983958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.
    Lima FP; Bousquet M; Gomez-Brouchet A; de Paiva GR; Amstalden EM; Soares FA; Dastugue N; Vassallo J; Brousset P
    Am J Clin Pathol; 2008 May; 129(5):723-6. PubMed ID: 18426731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
    Wang J; Young L; Win W; Taylor CR
    Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution architecture and partner genes of
    Chong LC; Ben-Neriah S; Slack GW; Freeman C; Ennishi D; Mottok A; Collinge B; Abrisqueta P; Farinha P; Boyle M; Meissner B; Kridel R; Gerrie AS; Villa D; Savage KJ; Sehn LH; Siebert R; Morin RD; Gascoyne RD; Marra MA; Connors JM; Mungall AJ; Steidl C; Scott DW
    Blood Adv; 2018 Oct; 2(20):2755-2765. PubMed ID: 30348671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
    Haralambieva E; Boerma EJ; van Imhoff GW; Rosati S; Schuuring E; Müller-Hermelink HK; Kluin PM; Ott G
    Am J Surg Pathol; 2005 Aug; 29(8):1086-94. PubMed ID: 16006805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma.
    Smith SM; Anastasi J; Cohen KS; Godley LA
    Blood Cells Mol Dis; 2010 Dec; 45(4):317-23. PubMed ID: 20817505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors.
    Chisholm KM; Krishnan C; Heerema-McKenney A; Natkunam Y
    Pediatr Dev Pathol; 2017 Jun; 20(3):213-223. PubMed ID: 28521631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement.
    Barth TF; Müller S; Pawlita M; Siebert R; Rother JU; Mechtersheimer G; Kitinya J; Bentz M; Möller P
    J Pathol; 2004 Aug; 203(4):940-5. PubMed ID: 15258997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathology consultation on intermediate-to-large B-cell lymphomas.
    Montgomery ND; Fedoriw Y
    Am J Clin Pathol; 2014 Mar; 141(3):305-17. PubMed ID: 24515757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
    da Cunha Santos G; Ko HM; Saieg MA; Boerner SL; Lai SW; Bailey D; Geddie WR
    Cancer Cytopathol; 2011 Aug; 119(4):254-62. PubMed ID: 21560251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.
    Muñoz-Mármol AM; Sanz C; Tapia G; Marginet R; Ariza A; Mate JL
    Histopathology; 2013 Sep; 63(3):418-24. PubMed ID: 23795946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytopathology of "double-hit" non-Hodgkin lymphoma.
    Elkins CT; Wakely PE
    Cancer Cytopathol; 2011 Aug; 119(4):263-71. PubMed ID: 21560252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.